bexarotene has been researched along with Sezary Syndrome in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (52.50) | 29.6817 |
| 2010's | 11 (27.50) | 24.3611 |
| 2020's | 8 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadu, C; Armstrong, N; Chalker, A; Duffy, S; Grimm, SE; Hiligsmann, M; Joore, MA; Kleijnen, J; Ryder, S; Syndikus, I; Wijnen, B; Witlox, W; Wolff, R | 1 |
| Ardigò, M; Cicini, MP; Franceschini, C; Mandel, VD; Saraceni, PL; Teoli, M | 1 |
| Christensen, LF; Cooper, KD; Ellis, A; Kord, H; Meyerson, H; Sharma, T | 1 |
| Briones, J; Espeso, M; Martín, A; Mozos, A; Novelli, S; Sánchez, JJ | 1 |
| Benoit, B; Berg, S; Clark, RA; Del Guzzo, C; Durgin, JS; Haun, PL; Inverso, J; Jariwala, NN; Kim, EJ; Lewis, DJ; Maity, A; Plastaras, JP; Rook, AH; Rosenthal, JM; Samimi, SS; Teague, JE; Villasenor-Park, J; Vittorio, C; Wysocka, M; Zhang, KK | 1 |
| Foss, F; Montanari, F; Reddy, N; Sethi, TK | 1 |
| Zic, JA | 1 |
| Einar French, L; Guertler, A; Helene Frommherz, L; Kaemmerer, T; Reinholz, M; Stadler, PC | 1 |
| Assaf, C; Nicolay, JP | 1 |
| Calderon Cabrera, C; Carrillo Cruz, E; de la Cruz Vicente, F; Espigado Tocino, I; Falantes, JF; Marín-Niebla, A; Martino Galiana, ML; Perez-Simón, JA; Prats Martín, C; Rios Herranz, E | 1 |
| Greer, JP; Likhari, SB; Mask-Bull, L; Zic, JA | 1 |
| Fabri, M; Felcht, M; Herling, M; Klemke, CD; Mrotzek, C; Schlaak, M; Schrader, A; Sommer, A | 1 |
| Huen, AO; Kim, EJ | 1 |
| Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S | 1 |
| Arulogun, S; Eaton, E; Gambell, P; Lade, S; McCormack, C; Prince, HM; Ryan, G | 1 |
| Abbott, RA; Bashir, SJ; Hung, T; Morris, SL; Russell-Jones, R; Scarisbrick, JJ; Whittaker, SJ | 1 |
| Akay, BN; Ozcan, M; Sanli, H | 1 |
| Bagot, M; Bensussan, A; Caudron, A; Marie-Cardine, A | 1 |
| Schmidt, C | 1 |
| Cheeley, J; DeLong, LK; Parker, SR; Sahn, RE | 1 |
| Assaf, C; Becker, JC; Dummer, R; Duvic, M; Grazia Bernengo, M; Lebbé, C; Marshood, M; Ortiz Romero, P; Poulalhon, N; Prince, HM; Squier, M; Tai, F; Williams, D | 1 |
| Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC | 1 |
| Andreeff, M; Duvic, M; Konopleva, M; Ni, X; Zhang, C | 1 |
| Foss, F | 1 |
| Bouwhuis, SA; el-Azhary, RA | 1 |
| Benoit, B; Budgin, JB; Newton, SB; Richardson, SK; Rook, AH; Wysocka, M; Zaki, MH | 1 |
| Bouwhuis, SA; Davis, MD; el-Azhary, RA; Gibson, LE; Kist, JM; Knudsen, JM; McEvoy, MT; Pittelkow, MR | 1 |
| Biagi, J; Brennand, S; Kennedy, G; McCormack, CJ; Prince, HM; Seymour, JF; Sutton, VR; Trapani, JA; Westerman, D | 1 |
| Junkins-Hopkins, JM; Kim, EJ; McGinnis, KS; Newton, S; Rook, AH; Ubriani, R; Vittorio, CC; Wysocka, M | 1 |
| Altmeyer, P; Kreuter, A | 1 |
| Camacho, F; Carrizosa-Esquivel, A; Herrera-Saval, A; Rios-Martín, JJ; Ruiz-de-Casas, A | 1 |
| Burg, G; Dummer, R; Hauschild, A; Skalsky, J; Weichenthal, M | 1 |
| Dervenoulas, J; Economopoulos, T; Giannopoulou, V; Girkas, K; Kaitsa, I; Kapsimali, V; Papageorgiou, E; Papageorgiou, S; Pappa, V; Stavrianeas, N; Tsirigotis, P | 1 |
| Benoit, BM; Newton, SB; Rook, AH; Wysocka, M; Yoon, JS | 1 |
| Abrams, CS; Bach, TL; Benoit, BM; Budgin, JB; Lin, JH; Newton, SB; Richardson, SK; Rook, AH; Wysocka, M; Yoon, JS | 1 |
| Bagazgoitia, L; Harto, A; Jaén, P; Muñoz, E; Pérez-Carmona, L; Ríos, L | 1 |
| Bagot, M | 1 |
| Ranki, A | 1 |
| Scharffetter-Kochanek, K; Staib, G | 1 |
| Duvic, M | 1 |
10 review(s) available for bexarotene and Sezary Syndrome
| Article | Year |
|---|---|
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bexarotene; Cost-Benefit Analysis; Humans; Mycosis Fungoides; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sezary Syndrome; Skin Neoplasms; State Medicine; Technology; Technology Assessment, Biomedical; Vorinostat | 2022 |
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Male; Mycosis Fungoides; Neoplasm Staging; Neoplastic Stem Cells; Photopheresis; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Signal Transduction; Skin Neoplasms; T-Lymphocyte Subsets | 2021 |
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms | 2021 |
[Treatment of mycosis fungoides and Sézary syndrome].
Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization | 2017 |
Hemagglutination during photopheresis.
Topics: Aged; Bexarotene; Combined Modality Therapy; Follow-Up Studies; Hemagglutination, Viral; Herpes Zoster; Humans; Male; Photopheresis; Risk Assessment; Severity of Illness Index; Sezary Syndrome; Tetrahydronaphthalenes; Treatment Outcome | 2014 |
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Humans; Hyperlipidemias; Hypothyroidism; Immunologic Factors; Interferons; Mycosis Fungoides; PUVA Therapy; Retinoids; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
[New developments in Sézary syndrome].
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Combined Modality Therapy; Diphtheria Toxin; Disease Models, Animal; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Interleukin-2; Mice; Mice, SCID; Molecular Targeted Therapy; Photopheresis; PUVA Therapy; Receptors, KIR3DL2; Recombinant Fusion Proteins; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Therapies, Investigational | 2012 |
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Female; Ficusin; Humans; Male; Middle Aged; Photosensitizing Agents; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2003 |
Mycosis fungoides and the Sézary syndrome.
Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; Neoplasm Staging; Prognosis; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2004 |
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biopsy; Carmustine; Disease Progression; Drug Eruptions; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Neoplasm Staging; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Tetrahydronaphthalenes; Vitamin D | 2001 |
1 trial(s) available for bexarotene and Sezary Syndrome
| Article | Year |
|---|---|
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Disease Progression; Disease-Free Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Mycosis Fungoides; Panobinostat; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2013 |
29 other study(ies) available for bexarotene and Sezary Syndrome
| Article | Year |
|---|---|
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
Topics: Adult; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms | 2022 |
CD30
Topics: Aged; Bexarotene; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Treatment Outcome; Vorinostat | 2021 |
Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Palliative Care; Prednisone; Referral and Consultation; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Spain; Survival Analysis; Transplantation, Homologous; Vincristine | 2020 |
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Combined Modality Therapy; Electrons; Humans; Immunotherapy; Interferon-gamma; Male; Middle Aged; Photopheresis; Radiotherapy Dosage; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Treatment Outcome | 2021 |
Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Topics: Adult; Aged; Alitretinoin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Sezary Syndrome; Skin Neoplasms | 2021 |
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Humans; Mycosis Fungoides; Pentostatin; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
Vitamin D controls apoptosis and proliferation of cutaneous T-cell lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Bexarotene; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Mycosis Fungoides; Receptors, Calcitriol; Retinoid X Receptors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Vitamin D; Vitamin D Deficiency | 2015 |
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cholesterol, HDL; Combined Modality Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2016 |
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cohort Studies; Disease-Free Survival; Female; Humans; Interferon-alpha; Male; Methotrexate; Middle Aged; Photopheresis; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2008 |
Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Cohort Studies; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sex Factors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
Topics: Adult; Anticarcinogenic Agents; Bexarotene; Hodgkin Disease; Humans; Male; Sezary Syndrome; Tetrahydronaphthalenes | 2010 |
Cutaneous T-cell lymphoma's confounding nature.
Topics: Aged; Alemtuzumab; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brentuximab Vedotin; Delayed Diagnosis; Diagnosis, Differential; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Remission Induction; Sezary Syndrome; Stem Cell Transplantation; Tetrahydronaphthalenes; Transplantation, Homologous | 2012 |
Acitretin for the treatment of cutaneous T-cell lymphoma.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Topics: Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Immunologic Factors; Ligands; Lymphocytes; Mycosis Fungoides; Nitric Oxide; Oleanolic Acid; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Transcription Factors | 2004 |
Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
Topics: Administration, Oral; Antineoplastic Agents; Bexarotene; Dermatitis, Exfoliative; Erythema; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Pruritus; Retinoid X Receptors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2005 |
Biological effects of bexarotene in cutaneous T-cell lymphoma.
Topics: Apoptosis; Bexarotene; Case-Control Studies; Cytokines; Drug Synergism; Female; Flow Cytometry; Humans; Interferon-alpha; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Male; Reference Values; Risk Factors; Sensitivity and Specificity; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2005 |
Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Topics: Adult; Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2005 |
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Apoptosis; Bexarotene; Female; Humans; In Situ Nick-End Labeling; Male; Middle Aged; Neoplastic Cells, Circulating; Sezary Syndrome; Skin Neoplasms; Staining and Labeling; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2005 |
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
Topics: Administration, Oral; Bexarotene; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Photopheresis; Recombinant Proteins; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2005 |
Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome.
Topics: Aged; Bexarotene; CD8-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell; Male; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors | 2005 |
Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
Topics: Adult; Antineoplastic Agents; Bexarotene; Drug Eruptions; Fatal Outcome; Female; Granuloma; Humans; Sezary Syndrome; Tetrahydronaphthalenes | 2006 |
Bexarotene and systemic disease progression in CTCL?
Topics: Antineoplastic Agents; Bexarotene; Disease Progression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Reproducibility of Results; Risk Factors; Sezary Syndrome; Tetrahydronaphthalenes | 2006 |
Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Tetrahydronaphthalenes | 2007 |
Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome.
Topics: Antineoplastic Agents; Apoptosis; Bexarotene; CD4-Positive T-Lymphocytes; Cell Culture Techniques; Drug Resistance, Neoplasm; Humans; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2007 |
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Case-Control Studies; Cells, Cultured; Chemokine CCL17; Chemokines, CC; Chemotaxis, Leukocyte; Drug Evaluation, Preclinical; Female; Flow Cytometry; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Receptors, CCR4; Receptors, Chemokine; Sezary Syndrome; Tetrahydronaphthalenes; Time Factors | 2007 |
Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.
Topics: Anticarcinogenic Agents; Bexarotene; Dermatitis, Exfoliative; Female; Humans; Keratinocytes; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2008 |
Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunologic Factors; Interferon-alpha; Methotrexate; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2008 |
Bexarotene combination therapy for patients with Sézary syndrome.
Topics: Antineoplastic Agents; Atorvastatin; Bexarotene; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Bexarotene monotherapy for patients with refractory Sézary syndrome.
Topics: Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2008 |